CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC Impact of Transcatheter Mitral Valve Repair on Preprocedural and Postprocedural Hospitalization Rates Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients With Cancer Implications of the local hemodynamic forces on the formation and destabilization of neoatherosclerotic lesions Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses: MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study Long-Term Outcomes of Patients With Mediastinal Radiation–Associated Coronary Artery Disease Undergoing Coronary Revascularization With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure Results From the CABANA Trial Cardio-oncology: A Focus on Cardiotoxicity

Original ResearchApr 03, 2022

JOURNAL:JACC Clin Electrophysiol Article Link

Clinical Impact of Residual Leaks Following Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry

M Alkhouli, CA Du , A Killu et al.

ABSTRACT

BACKGROUND - Data on the impact of residual peri-device leak after left atrial appendage occlusion (LAAO) are limited.

 

OBJECTIVES - The goal of this study was to explore the association of peri-device leak with adverse clinical events.

 

METHODS - The National Cardiovascular Data Registry LAAO Registry was queried to identify patients undergoing LAAO between January 1, 2016, and December 31, 2019. Patients were classified according to leak size on echocardiography at 45 ± 14 days (0 mm, no leak; >0-5 mm, small leak; and >5 mm, large leak).

 

RESULTS - A total of 51,333 patients were included, of whom 37,696 (73.4%) had no leak, 13,258 (25.8%) had small leaks, and 379 (0.7%) had large leaks. The proportion of patients on warfarin at 45 days was higher in the large vs small or no leak cohorts (44.9% vs 34.4% and 32.4%, respectively; P < 0.001). At 6 and 12 months, anticoagulant utilization decreased but remained more frequent in patients with large leaks. Thromboembolic and bleeding events were uncommon in all groups. However, compared with patients with no leak, those with small leaks had slightly higher odds of stroke/transient ischemic attack/systemic embolization (adjusted HR: 1.152; 95% CI: 1.025-1.294), major bleeding (HR: 1.11; 95% CI: 1.029-1.120), and any major adverse events (HR: 1.102; 95% CI: 1.048-1.160). There were no significant differences in adverse events between patients with large leaks and patients with small or no leaks.

 

CONCLUSIONS - Small (>0-5 mm) leaks after LAAO were associated with a modestly higher incidence of thromboembolic and bleeding events; large leaks (>5 mm) were not associated with adverse events, although higher proportions of these patients were maintained on anticoagulation. Newer devices with improved seal might mitigate the events associated with residual leaks.